GridAI Technologies Corp
enterothera.comWhat Do They Do?
Develops energy orchestration and grid optimization software for AI data centers and other large energy users, alongside Adrulipase, a drug candidate for pancreatic insufficiency.
10-K for FY2025, filed May 1, 2026
How Do They Make Money?
Energy sales under long-term contracts earn revenue when power is generated and sent to the grid; engineering and construction work earns revenue as projects progress, and operation and maintenance services over time.
10-K for FY2025, filed May 1, 2026Energy generation revenue is generated primarily from contracts with various non-affiliated parties under long-term power purchase…View ↗
The Company recognizes revenue for sale of EPC and development services over time based on the estimated progress to completion using a…View ↗
Operation and maintenance (“O&M”) services are transferred over time when customers receive and consume the benefits provided by the…View ↗
$36.3K
-
10-K for FY2025, filed May 1, 2026
$36.3K ↗
Who Are Their Customers?
Targets enterprise and government operators of large data center campuses and other large energy users. It plans direct sales and commercial deployment through energy developers, system integrators and engineering firms.
10-K for FY2025, filed May 1, 2026Grid AI Corp. develops software and services designed to accelerate power availability and optimize energy infrastructure for artificial…View ↗
Target customers include enterprise and government entities operating large data center campuses.View ↗
Gris Ai Corp. markets its legacy technologies and intends to pursue commercial deployment of its AI data center platform through direct…View ↗
Do Revenues Turn Into Profits?
No. It lost $6.4M in FY2025.
10-K for FY2025, filed May 1, 2026
How Are They Changing?
From drug research to energy software
The earlier report describes a business developing gastrointestinal drug candidates, including Adrulipase and niclosamide. The latest report adds energy orchestration and grid optimization software, focuses strategically on AI data center energy systems, and retains Adrulipase as a legacy development program.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed May 1, 2026GridAI Technologies Corp., formerly known as Entero Therapeutics, Inc., is a diversified technology and life sciences company operating…View ↗
Grid AI Corp. develops software and services designed to accelerate power availability and optimize energy infrastructure for artificial…View ↗
As of December 31, 2025, our legacy biopharmaceutical activities are centered on Adrulipase, our recombinant lipase enzyme program for the…View ↗
Who Do They Compete With?
Competes with AbbVie, Nestlé Health Science, VIVUS, and Chiesi Farmaceutici
10-K for FY2025, filed May 1, 2026CREON® marketed by AbbVie Inc.View ↗
Loading...
